Mutational analysis in a patient with a variant form of Gaucher disease caused by SAP-2 deficiency
- 1 January 1993
- journal article
- case report
- Published by Springer Nature in Somatic Cell and Molecular Genetics
- Vol. 19 (1), 1-7
- https://doi.org/10.1007/bf01233949
Abstract
It is now clear that the lysosomal hydrolysis of sphingolipids requires both lysosomal enzymes and so-called sphingolipid activator proteins (SAPs). One gene, called prosaposin, codes for a precursor protein that is proteolytically cut into four putative SAPs. These four SAPs, of about 80 amino acids, share some structural features but differ somewhat in their specificity. Domain 3 of prosaposin mRNA contains the coding region for SAP-2, an activator of glucocerebrosidase. While most patients with Gaucher disease store glucosylceramide due to defects in glucocerebrosidase, a few patients store this lipid in the presence of normal enzyme levels. In this paper we describe the identification of a point mutation in domain 3 of a patient who died with this variant form of Gaucher disease. Polymerase chain reaction amplification was performed in the small amount of genomic DNA available using primers generated from the intronic sequence s surrounding domain 3. The patient was found to have a T-to-G substitution at position 1144 (counting from the A of ATG initiation codon) in half of the M13 recombinant clones. This changes the codon for cysteine382 to glycine. His father and unaffected brother also had this mutation, but his mother did not. She was found to have half of the normal amount of mRNA for prosaposin in her cultured skin fibroblasts. Therefore, this child inherited a point mutation in domain 3 from his father and a deficiency of all four SAPs coded for by prosaposin from his mother.Keywords
This publication has 23 references indexed in Scilit:
- Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher diseaseFEBS Letters, 1991
- Sphingolipid activator protein 1 deficiency in metachromatic leucodystrophy with normal arylsulphatase A activity. A clinical, morphological, biochemical and immunological studyEuropean Journal of Pediatrics, 1991
- Detection of a point mutation in sphingolipid activator protein-1 mRNA in patients with a variant form of metachromatic leukodystrophyBiochemical and Biophysical Research Communications, 1990
- Activator protein deficient Gaucher's diseaseKlinische Wochenschrift, 1989
- Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: Biochemical signs of combined sphingolipidosesEuropean Journal of Pediatrics, 1989
- Molecular cloning of a human co-β-glucosidase cDNA: Evidence that four sphingolipid hydrolase activator proteins are encoded by single genes in humans and ratsGenomics, 1989
- Clinical, pathological, and biochemical studies on an infantile case of sulfatide/GM1 activator protein deficiencyAmerican Journal of Medical Genetics, 1989
- Coding of Two Sphingolipid Activator Proteins (SAP-1 and SAP-2) by Same Genetic LocusScience, 1988
- Biosynthesis of the sulfatide/GM1 activator protein (SAP-1) in control and mutant cultured skin fibroblastsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1986
- A variant form of metachromatic leukodystrophy without arylsulfatase deficiencyAnnals of Neurology, 1982